Lansing, Michigan — According to state and local development sources, IONETIX Corporation plans to invest $25,750,000.00 to expand in Lansing. The company plans to occupy the new space in Lansing, on or about July 1, 2026. According to the company website Ionetix is a cyclotron and technology company providing full-service radioisotope production and end-to-end radiopharmaceutical manufacturing solutions by actively establishing a network of ION-12SCs installed on or near the campus of PET programs across the country. By covering all costs related to the installation and ongoing operation of the cyclotron and making N-13 Ammonia available to providers through a pay-by-the-dose model, we are making this critical tracer accessible and affordable to providers nationwide. Our more recent endeavors involve leveraging our growing network of radiopharmaceutical manufacturing locations to support the development and commercialization of targeted alpha therapy (TAT), an emerging cancer therapy utilizing alpha radionuclides. The time is now to harness the power to deliver cutting edge diagnostics and therapeutics. We encourage you to visit our website for more information or message our LinkedIn page with any questions.

To learn more about IONETIX Corporation, visit http://www.ionetix.com/

Company Contact:
Kevin Cameron, Chief Executive Officer
517-252-4069

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.